MAVENIR
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announced today that together with O2 Telefónica, have demonstrated simplified deployment and change management on Core network elements, leveraging a common Zero Touch Continuous Integration, Continuous Deployment and Continuous Testing (CI/CD/CT) framework in O2 Telefónica’s German network. This will streamline operations in O2 Telefónica OpCos with leaner operations, faster deployments, and simplified operational changes in the network.
This is a significant milestone in the evolution of streamlined operations, moving away from manual deployments and reducing human error. CI/CD provides greater flexibility for customers in day-to-day Operations and is expected to deliver significant benefits in terms of speed and cost of deployment.
Mavenir will work with O2 Telefónica to automate the Network Operations, enabling the transition to the adoption of the virtualized Network Functions. Mavenir’s CI/CD/CT framework will allow for creating customized workflows/processes for fast, agile change management in increased complexity 4G/5G networks. Mavenir’s solution is Opensource-based, interoperable, standardized technology that can be integrated in a “plug and play” manner for any VNF functions.
“5G requires cloud-native and microservices architecture but brings along more operational complexity in the network. CI/CD/CT based zero-touch deployment and change management is our way to be agile and accelerate time to market. This is a key strategy in the path of automation of our networks to achieve leaner and meaner Operations. Mavenir is a trusted and reliable partner for this journey, given the know-how and the experience we have with them in Core & Cloud projects,” said Jochen Bockfeld, Director Common Services, O2 Telefónica Deutschland .
Omar Shahdad, Senior Vice President Global Operations, Mavenir said, “We are honored to have been chosen by O2 Telefónica for this vital part of their network simplification journey. Mavenir is uniquely qualified to provide CI/CD services in the Telco space due to our extensive know-how spanning multiple Telco domains. We are a company that prides itself in its speed, agility, responsiveness, and those are the same required characteristics of a CI/CD program. Mavenir’s solution utilizes high levels of automation and integration that enables our customers to harness the benefits of cloud-native and virtual networks to manage complexity and allow hybrid operations for increased flexibility.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About O2 Telefónica:
O2 Telefónica Deutschland offers telecommunications services for consumers and business customers as well as innovative digital products and services in the area of the Internet of Things and data analytics. The company is one of the leading integrated telecommunications providers in Germany. In mobile communications alone, O2 Telefónica serves more around 46 million mobile lines (incl. M2M - as of 31.12.2021). No network operator connects more people in this country. Under its core brand O2 and various secondary and partner brands, the company sells postpaid and prepaid mobile communications products with innovative mobile data services. The basis for this is the mobile communications network based on a highly resilient GSM, UMTS and LTE infrastructure. At the same time, the company is building a powerful and energy-efficient 5G network. O2 Telefónica also provides telephony and high-speed Internet products based on various technologies in the fixed-network area. Telefónica Deutschland Holding AG has been listed in the Prime Standard segment of the Frankfurt Stock Exchange (TecDAX) since 2012. In the 2021 financial year, the company generated revenue of EUR 7,8 billion with around 7.400 employees. The company is majority-owned by the Spanish telecommunications group Telefónica S.A., headquartered in Madrid. With business activities in 14 countries and a customer base of around 369 million lines, the Group is one of the world's largest telecommunications providers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005203/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e
AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release
Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom